Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of pemafibrate and tofogliflozin alone or in combination for noncirrhotic NASH with liver fibrosis
2021-003901-23Phase 2Active
- Sponsor
- Kowa Research Institute
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pemafibrate and tofogliflozin in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis (4 arms), sponsored by Kowa Research Institute. Primary endpoint: Histological improvement in disease activity without worsening of fibrosis at Week 48. Started Dec 2021; status: active.
02
Drugs
pemafibratetofogliflozin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on 2021-003901-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003901-23.